Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

Abstract Background Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab p...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Miguel Quintela-Fandino, Esther Holgado, Luis Manso, Serafin Morales, Begoña Bermejo, Ramon Colomer, Juan V. Apala, Raquel Blanco, Manuel Muñoz, Eduardo Caleiras, Vega Iranzo, Mario Martinez, Orlando Dominguez, Javier Hornedo, Lucia Gonzalez-Cortijo, Javier Cortes, Ariadna Gasol Cudos, Diego Malon, Antonio Lopez-Alonso, María C. Moreno-Ortíz, Silvana Mouron, Santos Mañes
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2020-11-01
coleção:	Breast Cancer Research
Assuntos:	Durvalumab Bevacizumab HER2-negative breast cancer Vascular normalization Immuno-priming
Acesso em linha:	http://link.springer.com/article/10.1186/s13058-020-01362-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!